Lymphangioleiomyomatosis (LAM): High-Resolution CT Diagnosis, Differential Diagnosis, Treatment, and Prognosis in a 40-Year-Old Woman
Lymphangioleiomyomatosis: When Hundreds of Lung Cysts Tell the Diagnosis
A 40-year-old woman has experienced gradually progressive shortness of breath for approximately two years. During the most recent four months, her symptoms have become substantially worse.
At first glance, such a presentation could easily be attributed to asthma, deconditioning, chronic airway disease, or another common pulmonary disorder.
But the clinical picture changes dramatically when a high-resolution chest CT reveals something striking: both lungs are filled with innumerable, relatively thin-walled cysts of varying sizes, extending from the upper lungs through the bases.
This is the moment when medical imaging becomes more than a confirmatory test.
It becomes the diagnostic language of the disease.
The pattern strongly raises the possibility of lymphangioleiomyomatosis (LAM), a rare multisystem disorder characterized by abnormal proliferation of LAM cells, progressive destruction of lung parenchyma, and formation of diffuse pulmonary cysts.
The supplied case describes a 40-year-old woman with progressive dyspnea and extensive bilateral cystic destruction, with more than 80% of the lung parenchyma described as replaced by cystic change.
LAM is rare, but its thoracic imaging pattern can be remarkably recognizable. For radiologists, pulmonologists, emergency physicians, and clinicians interpreting MRI, CT, and chest imaging, recognizing this pattern can shorten the diagnostic pathway and prevent inappropriate procedures.
Modern LAM management has also changed substantially. The disease is no longer regarded simply as an inexorably progressive rare lung disorder. Understanding of the TSC–mTOR pathway has led to targeted therapy with sirolimus, while selected patients with advanced respiratory failure may be considered for lung transplantation.
This article examines LAM from a radiology-first perspective, emphasizing CT pattern recognition, differential diagnosis, diagnostic workflow, disease monitoring, and treatment implications.
1. What Is Lymphangioleiomyomatosis?
Lymphangioleiomyomatosis is a rare systemic disease characterized by proliferation of abnormal smooth-muscle-like LAM cells involving the lungs and, in some patients, lymphatic and extrapulmonary structures.
Clinically, LAM occurs overwhelmingly in women and most commonly presents during the reproductive years.
There are two major clinical settings:
Sporadic LAM
Tuberous sclerosis complex–associated LAM (TSC-LAM)
The disease is closely related to abnormal activation of the mechanistic target of rapamycin (mTOR) pathway.
TSC1 and TSC2 are important regulators of mTOR signaling. Abnormalities involving this pathway can promote cellular growth and proliferation. This molecular understanding provides the biological rationale for mTOR inhibition with sirolimus.
The disease is therefore best understood not simply as a pulmonary cystic disorder, but as a systemic mTOR-driven neoplastic process with characteristic pulmonary manifestations.
A 2025 review emphasizes that the contemporary understanding of LAM increasingly encompasses interactions among mTOR signaling, hormonal pathways, immune mechanisms, and the LAM microenvironment, as new therapeutic approaches are being investigated.
2. Why Does LAM Produce So Many Lung Cysts?
The central radiologic question is simple:
Why does a systemic disease produce hundreds or thousands of cystic spaces throughout both lungs?
LAM cells proliferate around structures including:
Small airways
Blood vessels
Lymphatic channels
The resulting cellular proliferation and remodeling can progressively obstruct small airways and interfere with normal pulmonary architecture.
Air trapping, tissue destruction, and remodeling ultimately produce numerous cystic spaces.
The important point for radiology interpretation is that these cysts are not incidental simple pulmonary cysts.
They are the structural expression of disease.
As LAM progresses:
The supplied case material emphasizes that cyst number and size can increase with disease progression, eventually leaving very little normal-appearing lung parenchyma.
This explains why quantitative CT and longitudinal imaging are becoming increasingly relevant.
3. Who Develops LAM?
LAM is strongly associated with female sex and is most often recognized in women of reproductive age.
The demographic context is therefore an important part of medical imaging interpretation.
A radiologist encountering:
woman + progressive unexplained dyspnea + diffuse bilateral lung cysts
should immediately consider LAM.
Additional clinical clues include:
Recurrent spontaneous pneumothorax
Chylous pleural effusion
Hemoptysis
Progressive exercise limitation
Hypoxemia in advanced disease
Renal angiomyolipoma
Lymphatic abnormalities
Features of tuberous sclerosis complex
The supplied case specifically describes a 40-year-old woman with approximately two years of progressive dyspnea and marked deterioration during the preceding four months.
This combination is highly relevant when interpreting a chest CT.
4. Clinical Presentation: The Symptoms Are Often Nonspecific
LAM can remain clinically elusive for years.
The most common symptom is progressive dyspnea.
Other manifestations include:
| Clinical manifestation | Diagnostic significance |
|---|---|
| Progressive dyspnea | Common presenting symptom |
| Dry cough | Frequently associated |
| Chest pain | May reflect pulmonary or pleural complications |
| Spontaneous pneumothorax | Important complication |
| Chylous pleural effusion | Indicates lymphatic involvement |
| Hemoptysis | Occasional |
| Reduced exercise tolerance | Reflects declining pulmonary reserve |
| Hypoxemia | More common with advanced disease |
| Pulmonary hypertension | Possible late complication |
A sudden increase in chest pain and dyspnea in a known LAM patient deserves special attention.
The first question should be:
Has a pneumothorax developed?
Because cysts can rupture into the pleural space, spontaneous pneumothorax is an important complication.
5. Figure 1 — Chest CT Scout Image
Figure 1. Chest CT scout image demonstrating diffuse pulmonary abnormality in a patient with LAM.
Radiologic interpretation: The scout image demonstrates generalized pulmonary abnormality with increased lung lucency and diffuse interstitial/reticular-appearing changes. However, the scout image cannot adequately characterize the walls, morphology, or distribution of individual pulmonary cysts.
Diagnostic contribution: The scout image should be regarded as a screening projection rather than a definitive diagnostic examination. When diffuse pulmonary abnormality is suspected, thin-section HRCT is required for detailed assessment. The case material specifically emphasizes that a relatively nonspecific chest radiograph or scout image should not be used to exclude LAM.
6. Why HRCT Is the Most Important Imaging Examination
For suspected LAM, high-resolution computed tomography (HRCT) is the central imaging examination.
Unlike conventional radiography, CT allows the radiologist to systematically evaluate:
Whether a low-attenuation lesion is a true cyst
Cyst-wall thickness
Cyst morphology
Cyst size
Cyst distribution
Associated nodules
Ground-glass opacity
Interstitial abnormalities
Pneumothorax
Pleural effusion
Mediastinal findings
Extrapulmonary abnormalities
The classic LAM pattern consists of:
Numerous bilateral pulmonary cysts
Thin walls
Relatively smooth margins
Round or oval morphology
Variable cyst size
Diffuse distribution
Involvement of both upper and lower lungs
Extension to the lung bases
The supplied case describes extensive bilateral cystic disease with more than 80% of the lung parenchyma replaced by cystic abnormalities.
This degree of involvement represents advanced structural pulmonary disease.
7. Figure 2 — Axial Lung-Window CT
Figure 2. Axial lung-window CT demonstrating extensive bilateral thin-walled cystic lung disease.
Radiologic interpretation: Axial lung-window images demonstrate innumerable cystic spaces distributed throughout both lungs. The cysts have relatively thin walls and variable sizes and shapes. Importantly, the disease is not confined to one lobe or a particular regional compartment.
The dominant imaging pattern can be summarized as:
Diffuse bilateral distribution + numerous cysts + thin walls + variable size
This combination is highly characteristic of LAM.
The case source specifically describes extensive cystic involvement throughout both lungs and emphasizes the importance of assessing cyst morphology and distribution together rather than simply recording the presence of “lung cysts.”
8. Figure 3 — Sagittal Lung-Window CT
Figure 3. Sagittal lung-window CT demonstrating diffuse craniocaudal distribution of pulmonary cysts.
Radiologic interpretation: The sagittal reconstruction demonstrates numerous thin-walled cysts extending through the upper, middle, and lower lung regions, including the bases.
Why this matters: Multiplanar reconstruction is particularly useful when evaluating the overall spatial distribution of cystic disease.
LAM tends to involve the lungs diffusely.
This contrasts with pulmonary Langerhans cell histiocytosis (PLCH), which classically demonstrates upper- and mid-lung predominance with relative sparing of the costophrenic angles.
The supplied case specifically identifies involvement of the lung bases as an important discriminator between LAM and PLCH.
9. Figure 4 — Extensive Bilateral Cystic Lung Destruction
Figure 4. Coronal/multiplanar CT representation of advanced diffuse cystic lung involvement.
Radiologic interpretation: The lungs demonstrate extensive replacement by cystic spaces with relatively little preserved normal-appearing lung parenchyma. The cysts are variable in size but predominantly thin-walled and diffusely distributed.
This imaging appearance is important because it demonstrates the structural endpoint of progressive LAM.
The disease burden is no longer represented simply by the number of cysts.
Instead, the relevant imaging question becomes:
How much functional lung remains between the cysts?
In the supplied case, more than 80% of the pulmonary parenchyma is described as being replaced by cystic disease.
This degree of structural destruction explains severe exercise intolerance, progressive dyspnea, and the possibility of chronic respiratory failure.
10. Figure 5 — Diagnostic and Management Algorithm
Figure 5. Stepwise diagnostic and management algorithm for a young woman with multiple pulmonary cysts.
Radiologic interpretation: The algorithm emphasizes five major decision points:
Confirm that the lesions are true cysts.
Determine their distribution.
Assess for accompanying nodules.
Search for extrapulmonary abnormalities.
Integrate VEGF-D and clinical assessment.
The algorithm then progresses toward:
Typical LAM pattern → pulmonary function assessment → disease-severity evaluation → consideration of sirolimus → lung-transplant evaluation in advanced respiratory failure.
This approach reflects the central principle of modern cystic lung disease diagnosis: pattern recognition must be combined with clinical and systemic evaluation.
11. The Most Important CT Question: Is It Really a Cyst?
A low-attenuation region in the lung is not automatically a cyst.
This is one of the most important principles in diffuse cystic lung disease.
The differential includes:
True pulmonary cyst
Emphysema
Bulla
Cavity
Cystic bronchiectasis
Pneumatocele
Honeycombing
A systematic CT approach therefore begins with morphology.
Ask:
Does the lucent region have a definable wall?
A true cyst is generally a round or oval air-containing or fluid-containing space surrounded by an identifiable wall.
Emphysema, by contrast, generally produces low-attenuation areas without a discrete cyst wall.
This distinction is particularly important because LAM and emphysema can appear deceptively similar on axial CT.
The supplied material explicitly identifies the distinction between true cysts and emphysema, bullae, cavities, bronchiectasis, pneumatoceles, and honeycombing as the first major diagnostic step.
12. LAM Versus Emphysema
This is a classic radiology trap.
Both conditions may demonstrate extensive pulmonary lucency.
But their morphology differs.
LAM
Numerous discrete cysts
Thin but recognizable walls
Relatively uniform distribution
Frequently affects women of reproductive age
Can involve the lung bases
Emphysema
Low-attenuation spaces
Walls are generally absent or imperceptible
Distribution depends on emphysema subtype
Strong association with smoking in common clinical settings
Therefore:
When the lung looks unusually lucent, do not stop at “emphysema.” Look for cyst walls.
This single observation can redirect the entire diagnostic pathway.
13. LAM Versus Pulmonary Langerhans Cell Histiocytosis
PLCH is one of the most important differential diagnoses.
| Feature | LAM | PLCH |
|---|---|---|
| Typical demographic | Women, reproductive age | Strong smoking association |
| Cysts | Thin-walled, variable size | Often irregular/bizarre |
| Distribution | Diffuse | Upper/mid-lung predominant |
| Lung bases | Usually involved | Relatively spared |
| Nodules | Usually not dominant | Frequently present |
| Disease evolution | Cystic destruction | Nodules may evolve into cysts |
LAM generally produces diffuse cystic disease throughout the lungs.
PLCH tends to demonstrate a more upper-lung-predominant process with nodules and cysts.
The supplied case emphasizes the combination of upper and lower lung involvement without a dominant nodular component as strongly favoring LAM.
14. Other Major Differential Diagnoses
Birt-Hogg-Dubé Syndrome
BHD should be considered when cysts are:
Irregular
Lower-lung predominant
Subpleural
Basilar
A history of renal tumors, characteristic skin lesions, or familial spontaneous pneumothorax can provide additional clues.
Lymphocytic Interstitial Pneumonia
LIP may produce cysts, but associated findings such as:
Ground-glass opacity
Small nodules
Interstitial abnormalities
may provide important context.
LIP is also associated with autoimmune disorders, particularly Sjögren syndrome.
Cystic Bronchiectasis
Cystic bronchiectasis follows the architecture of dilated airways and is typically associated with:
Bronchial wall thickening
Lack of normal bronchial tapering
Airway-centered distribution
Bronchoarterial abnormalities
Honeycombing
Honeycombing usually represents advanced fibrotic interstitial lung disease and has a characteristic subpleural stacked/cystic appearance.
Emphysema
The absence of recognizable cyst walls is an important clue.
A systematic radiologic approach to cystic lung disease published in 2025 similarly emphasizes distinguishing true cysts from mimics such as emphysema, bullae, cavities, and honeycombing before assigning a specific cystic lung diagnosis.
15. The Extrapulmonary CT Findings That Can Strengthen the Diagnosis
LAM is not necessarily confined to the lungs.
When LAM is suspected, the radiologist should actively evaluate the abdomen and pelvis when clinically appropriate.
Important findings include:
Renal angiomyolipoma
Lymphangiomyoma
Retroperitoneal lymphatic lesions
Pelvic lymphatic lesions
Enlarged lymph nodes
Chylous collections
Renal angiomyolipoma is particularly useful because its macroscopic fat can be highly recognizable on CT.
A classic radiology study demonstrated that extrapulmonary abnormalities are common in patients with LAM, including renal angiomyolipoma and abdominal lymphatic abnormalities.
More recent Radiology literature has also highlighted multisystem LAM, including pulmonary cysts together with renal angiomyolipoma and pelvic/retroperitoneal lymphatic lesions.
Thus, when the chest CT suggests LAM, the examination should not end with the lungs.
16. Diagnosis: Is CT Alone Enough?
In a patient with a highly characteristic HRCT pattern, CT can provide an exceptionally strong diagnostic foundation.
However, diagnosis should not be reduced to a single image.
A modern diagnostic strategy integrates:
Clinical phenotype + HRCT + extrapulmonary findings + VEGF-D + pulmonary physiology
The ATS/JRS clinical practice guideline recommends a structured approach to diagnosis and management, including the use of serum VEGF-D in appropriate patients.
The supplied case material notes that serum VEGF-D levels of approximately 800 pg/mL or greater have been reported to provide high specificity in appropriate clinical contexts.
This should not be interpreted as a substitute for clinical judgment. A biomarker threshold must always be interpreted in context.
17. When Is Lung Biopsy Necessary?
One of the practical benefits of recognizing a classic imaging phenotype is the potential to avoid unnecessary invasive testing.
If a patient has:
Typical diffuse thin-walled cysts on HRCT
Compatible clinical presentation
Appropriate extrapulmonary findings and/or
Supportive VEGF-D elevation
then lung biopsy may not be necessary.
Conversely, tissue diagnosis can become important when:
Imaging is atypical
The differential diagnosis remains broad
VEGF-D is nondiagnostic
Extrapulmonary evidence is absent
Another disease would substantially change management
The radiologist therefore plays a critical role in deciding whether the CT pattern is sufficiently characteristic to support a noninvasive diagnostic pathway.
18. Treatment: From Observation to Targeted Therapy
LAM treatment is individualized.
Important factors include:
Symptoms
FEV1
Rate of lung-function decline
Exercise capacity
Oxygenation
Chylous complications
Pneumothorax history
Extrapulmonary disease
Treatment tolerance
Sirolimus and the mTOR Pathway
The major disease-modifying therapy is sirolimus, an mTOR inhibitor.
The landmark MILES trial demonstrated that sirolimus stabilized lung function in patients with LAM and moderate impairment rather than allowing the progressive decline seen with placebo.
The ATS/JRS guideline recommends sirolimus for patients with LAM who have abnormal or declining lung function, with the guideline defining abnormal lung function in this context as FEV1 below 70% predicted.
The key conceptual change is profound:
LAM is no longer simply a disease to observe until respiratory failure.
It is a disease in which targeted molecular therapy can modify the trajectory in appropriate patients.
19. What About Pneumothorax and Chylous Effusion?
Pulmonary cysts create structural vulnerability.
A ruptured cyst can produce spontaneous pneumothorax.
LAM patients may also develop chylous pleural effusions because of lymphatic involvement.
These complications may require:
Pleural intervention
Lymphatic-directed treatment
Sirolimus
Nutritional strategies
Interventional radiology procedures
Surgical management in selected circumstances
The precise strategy depends on severity and recurrence.
This is another reason why emergency diagnosis matters.
A woman with known or suspected LAM who develops sudden pleuritic chest pain and dyspnea should be evaluated promptly for pneumothorax.
20. Lung Transplantation in Advanced LAM
When LAM progresses to severe respiratory failure despite appropriate management, lung transplantation can become a treatment option.
The supplied case describes a patient with extremely advanced cystic destruction who underwent lung transplantation and subsequently survived for approximately seven years according to the clinical course presented in the source material.
Modern transplant literature supports lung transplantation as an important option for selected patients with end-stage LAM.
The important clinical message is:
Severe cystic destruction on CT should trigger assessment of functional reserve and longitudinal disease trajectory, not simply a descriptive radiology report.
21. Prognosis: CT Is Important, But CT Alone Is Not Enough
LAM behaves differently among individual patients.
Some patients remain relatively stable for long periods.
Others experience progressive decline in pulmonary function.
Prognostic assessment should incorporate:
FEV1
DLCO
Exercise capacity
Oxygen saturation
Rate of pulmonary-function decline
Cyst burden
Recurrent pneumothorax
Chylous complications
Pulmonary hypertension
Response to treatment
The supplied case specifically emphasizes that a single CT examination should not be used to predict an individual patient's long-term outcome.
Instead:
CT + pulmonary function + symptoms + complications + extrapulmonary disease
provides a more meaningful longitudinal assessment.
22. Quantitative CT and the Future of Medical Imaging
One of the most promising developments in LAM is the transition from qualitative to quantitative imaging.
Traditionally, a radiologist might describe:
“Extensive bilateral cystic change.”
But quantitative imaging asks a different question:
What percentage of the lung is affected, and how quickly is that percentage changing?
Quantitative CT can potentially measure:
Cyst volume
Cyst burden
Low-attenuation lung fraction
Preserved lung volume
Longitudinal change
Treatment-associated structural change
Research has explored CT-based quantification of disease progression and response to treatment in LAM.
The supplied case similarly identifies quantitative CT and AI-based cyst detection, lung segmentation, cyst burden estimation, and longitudinal analysis as emerging areas of interest.
This creates an important bridge between radiology interpretation, medical imaging AI, and precision medicine.
23. Could AI Improve LAM Imaging?
Potentially, yes.
LAM presents an attractive use case for AI because the disease produces a relatively repetitive structural phenotype.
Future clinical AI systems could potentially assist with:
Automated lung segmentation
The system first identifies the complete pulmonary volume.
Cyst detection
Deep-learning algorithms could detect individual cystic spaces.
Cyst burden quantification
The software could calculate the proportion of affected lung.
Longitudinal comparison
Serial CT examinations could be aligned and compared.
Decision support
The system could flag a pattern of:
female patient + diffuse thin-walled cysts + lower-lung involvement
and suggest consideration of LAM.
However, AI should remain a decision-support tool.
A computer-generated label is not a substitute for expert radiology interpretation.
The highest-value future system will likely integrate:
CT phenotype + demographics + pulmonary function + laboratory biomarkers + extrapulmonary findings
rather than interpreting the CT in isolation.
24. A Practical Radiology Checklist for LAM
When confronted with diffuse pulmonary cysts, ask these seven questions:
1. Are these true cysts?
Exclude emphysema, bullae, cavities, bronchiectasis, and honeycombing.
2. Are the cysts bilateral and diffuse?
Diffuse bilateral distribution strongly supports LAM in the appropriate patient.
3. Are the cyst walls thin?
Thin, relatively smooth walls are characteristic.
4. Are the lung bases involved?
Basilar involvement favors LAM over classic PLCH.
5. Are nodules prominent?
Numerous nodules should raise consideration of PLCH or other cystic/nodular disorders.
6. Are there extrapulmonary findings?
Search for:
Renal AML
Lymphatic lesions
Chylous collections
Retroperitoneal abnormalities
7. Does the clinical phenotype fit?
A woman with progressive dyspnea and recurrent pneumothorax is a particularly important clinical context.
25. The Diagnostic Algorithm in One Sentence
This workflow closely follows the structure presented in the supplied case algorithm.
26. Clinical Story: Why the CT Pattern Matters
Return to the 40-year-old woman.
For two years, she has gradually become more short of breath.
The symptoms are initially easy to normalize.
She may still be working.
She may still be walking.
She may have no dramatic abnormality on an initial chest radiograph.
But the disease is progressing silently.
Then CT is performed.
The radiologist sees the lungs almost filled with cystic spaces.
The distribution is diffuse.
The cysts are thin-walled.
The bases are involved.
There is no dominant nodular pattern suggesting PLCH.
The imaging pattern immediately changes the clinical conversation.
Instead of asking:
“What common lung disease causes this woman's dyspnea?”
the team begins asking:
“Could this be LAM, and how advanced is the disease?”
That change in diagnostic direction is one of the most important contributions of high-quality medical imaging.
The CT does not merely show anatomy.
It reveals the disease phenotype.
27. Key Takeaways
LAM is a rare systemic disease that predominantly affects women.
Progressive dyspnea is a common clinical presentation.
Spontaneous pneumothorax and chylous effusion are important complications.
HRCT is the central imaging examination for pulmonary LAM.
The classic pattern is multiple bilateral thin-walled cysts distributed diffusely throughout both lungs.
Lung-base involvement is an important discriminator from classic PLCH.
Always distinguish true cysts from emphysema, bullae, cavities, bronchiectasis, and honeycombing.
Renal angiomyolipoma and lymphatic abnormalities can provide important extrapulmonary clues.
Serum VEGF-D can support a noninvasive diagnostic strategy in appropriate patients.
Lung biopsy is not automatically required when the clinical and imaging phenotype is characteristic.
Sirolimus is an important disease-modifying therapy for appropriate patients with abnormal or declining lung function.
Advanced respiratory failure may lead to consideration of lung transplantation.
Quantitative CT and AI-based image analysis represent promising future tools for disease monitoring.
A single CT examination should not be used to determine an individual patient's entire prognosis.
28. Quiz
Question 1
A 40-year-old woman presents with progressive dyspnea. HRCT demonstrates numerous bilateral thin-walled cysts of variable size involving both upper and lower lungs, including the lung bases. Which diagnosis is most likely?
A. Pulmonary Langerhans cell histiocytosis
B. Emphysema
C. Lymphangioleiomyomatosis
D. Lymphocytic interstitial pneumonia
E. Cystic bronchiectasis
Correct answer: C. Lymphangioleiomyomatosis
Explanation
Diffuse bilateral thin-walled cysts involving the lung bases are highly characteristic of LAM in an appropriate female patient.
PLCH tends to favor the upper and middle lungs and may demonstrate nodules.
Emphysema generally lacks definable cyst walls.
LIP may demonstrate cysts but often has associated ground-glass opacity and nodules and occurs in an autoimmune clinical context.
Cystic bronchiectasis follows airway anatomy and demonstrates characteristic bronchial abnormalities.
The supplied case identifies this exact combination as the principal diagnostic pattern.
Question 2
Which laboratory biomarker can support the diagnosis of LAM in an appropriate clinical and imaging setting?
A. AFP
B. CA 19-9
C. VEGF-D
D. CEA
E. Procalcitonin
Correct answer: C. VEGF-D
Explanation
Serum vascular endothelial growth factor-D (VEGF-D) is an important biomarker in LAM.
It can be particularly useful when HRCT demonstrates a compatible cystic pattern but additional diagnostic confirmation is required.
The ATS/JRS guideline incorporates VEGF-D into the diagnostic approach, and the supplied case discusses a threshold around 800 pg/mL as having high specificity in appropriate settings.
The other biomarkers listed are associated with different clinical contexts and are not established diagnostic biomarkers for LAM.
Question 3
A patient with LAM has abnormal and declining pulmonary function. Which treatment most directly targets the disease's underlying molecular pathway?
A. Long-term antibiotic therapy
B. Sirolimus
C. Routine radiation therapy
D. Hormone replacement therapy
E. Observation regardless of disease progression
Correct answer: B. Sirolimus
Explanation
LAM is strongly associated with abnormal mTOR signaling.
Sirolimus inhibits mTOR signaling and has demonstrated disease-modifying effects in appropriate patients.
The MILES trial demonstrated stabilization of lung function with sirolimus in patients with LAM and moderate pulmonary impairment. The ATS/JRS guideline recommends sirolimus for patients with abnormal or declining lung function.
The supplied case also identifies sirolimus as the principal targeted therapy and notes that routine hormonal treatment is not the modern standard strategy.
29. Frequently Asked Questions
Is LAM a form of lung cancer?
LAM is not conventional lung carcinoma. Modern literature increasingly characterizes LAM as a low-grade, metastasizing neoplastic disorder involving abnormal LAM cells and mTOR pathway dysregulation.
Can a chest X-ray diagnose LAM?
Usually not reliably.
Radiography may show hyperinflation, reticular abnormalities, or other nonspecific changes, but HRCT provides much more definitive characterization of the cystic pattern.
What does LAM look like on CT?
The classic appearance is numerous bilateral, thin-walled, relatively smooth, round or oval cysts of variable size distributed diffusely throughout the lungs.
Does LAM affect the lower lungs?
Yes.
Diffuse involvement of the lower lungs and bases is an important feature and can help distinguish LAM from PLCH.
What is the most important differential diagnosis?
PLCH is one of the most important, but BHD, LIP, emphysema, cystic bronchiectasis, and other diffuse cystic lung diseases must also be considered.
Is lung biopsy always necessary?
No.
When the clinical presentation, HRCT pattern, extrapulmonary manifestations, and/or VEGF-D provide sufficient evidence, invasive tissue diagnosis may be avoidable.
What is VEGF-D?
VEGF-D is a lymphangiogenic growth factor that can be elevated in LAM. Serum VEGF-D can support diagnosis in appropriate patients.
Can LAM be treated?
Yes.
Sirolimus is an established disease-modifying treatment for appropriate patients, particularly those with abnormal or declining lung function.
Can LAM lead to respiratory failure?
Yes.
Progressive cystic destruction can substantially reduce functional lung tissue and eventually cause severe respiratory impairment.
Is lung transplantation possible?
Yes.
For selected patients with advanced, irreversible respiratory failure, lung transplantation can be considered.
Conclusion: The Radiologist Who Recognizes the Pattern Can Change the Diagnostic Journey
LAM is an excellent example of why expert medical imaging remains central to modern medicine.
The disease is rare.
The symptoms are often nonspecific.
The initial chest radiograph may be subtle.
But the CT pattern can be remarkably informative.
When a woman presents with progressive unexplained dyspnea and HRCT demonstrates numerous bilateral thin-walled cysts distributed throughout the lungs, including the bases, LAM should move rapidly toward the top of the differential diagnosis.
The next step is not simply to label the scan.
It is to determine whether the pattern is sufficiently characteristic, search for extrapulmonary manifestations, consider VEGF-D, evaluate pulmonary function, and communicate the implications to the clinical team.
The most important radiologic lesson is therefore simple:
Do not merely count the cysts. Read the pattern.
In LAM, the pattern contains the diagnosis.
And in advanced disease, the pattern also tells a story about how much lung has already been lost.
As quantitative CT, artificial intelligence, molecular biomarkers, and targeted therapy continue to evolve, the future of LAM diagnosis will increasingly connect radiology interpretation with precision medicine.
For the radiologist, however, the first step remains timeless:
Recognize the characteristic cystic pattern—and recognize it early.
Medical Disclaimer: This article is intended for educational purposes and does not replace individualized medical diagnosis or treatment. Patients with symptoms or abnormal imaging findings should be evaluated by qualified healthcare professionals.
Recommended Reading
F. X. McCormack et al., “Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management,” American Journal of Respiratory and Critical Care Medicine, vol. 194, no. 6, pp. 748–761, 2016. DOI: 10.1164/rccm.201607-1384ST.
DOI 10.1164/rccm.201607-1384STN. Gupta et al., “Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management,” American Journal of Respiratory and Critical Care Medicine, vol. 196, no. 10, pp. 1337–1348, 2017. DOI: 10.1164/rccm.201709-1965ST.
DOI 10.1164/rccm.201709-1965STF. X. McCormack et al., “Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis,” New England Journal of Medicine, vol. 364, no. 17, pp. 1595–1606, 2011. DOI: 10.1056/NEJMoa1100391.
DOI 10.1056/NEJMoa1100391C. McCarthy et al., “Lymphangioleiomyomatosis: Pathogenesis, Clinical Features, Diagnosis, and Management,” The Lancet Respiratory Medicine, vol. 9, no. 11, pp. 1313–1327, 2021. DOI: 10.1016/S2213-2600(21)00228-9.
DOI 10.1016/S2213-2600(21)00228-9V. Gopalakrishnan et al., “Use of CT Imaging to Quantify Progression and Response to Treatment in Lymphangioleiomyomatosis,” Chest, vol. 155, no. 5, pp. 962–971, 2019. DOI: 10.1016/j.chest.2019.01.004.
DOI 10.1016/j.chest.2019.01.004X. Dong et al., “A Systematic Review of Lymphangioleiomyomatosis on Diagnosis and Molecular Mechanism,” BioMed Research International, 2021, Article 6612776. DOI: 10.1155/2021/6612776.
DOI 10.1155/2021/6612776E. Hu-Wang et al., “Chest CT Scan at Radiation Dose of a Posteroanterior and Lateral Chest Radiograph Series: A Proof of Principle in Lymphangioleiomyomatosis,” Chest, vol. 155, no. 3, pp. 528–533, 2019. DOI: 10.1016/j.chest.2018.09.007.
DOI 10.1016/j.chest.2018.09.007K. Warrior and D. F. Dilling, “Lung Transplantation for Lymphangioleiomyomatosis,” Journal of Heart and Lung Transplantation, 2022. DOI: 10.1016/j.healun.2022.09.021.
DOI 10.1016/j.healun.2022.09.021J. J. Bissler et al., “Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis,” New England Journal of Medicine, vol. 358, no. 2, pp. 140–151, 2008. DOI: 10.1056/NEJMoa063564.
DOI 10.1056/NEJMoa063564F. Wang, “Multisystem Lymphangioleiomyomatosis,” Radiology, vol. 312, no. 2, 2024. DOI: 10.1148/radiol.240439.
DOI 10.1148/radiol.240439D. O'Malley, N. Gupta, and C. McCarthy, “Current Concepts in the Pathogenesis and Clinical Management of Lymphangioleiomyomatosis,” Current Opinion in Pulmonary Medicine, vol. 31, no. 5, pp. 494–503, 2025. DOI: 10.1097/MCP.0000000000001185.
DOI 10.1097/MCP.0000000000001185D. Elia et al., “Novel Treatment Strategies for Lymphangioleiomyomatosis: A Narrative Review,” European Respiratory Review, 2025. DOI: 10.1183/16000617.0019-2025.
DOI 10.1183/16000617.0019-2025
Comments
Post a Comment